PM
CRNX icon

Prosight Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Prosight Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14M Buy
374,666
+24,666
+7% +$917K 2.42% 15
2026
Q1 		$12.7M Buy
350,000
+87,096
+33% +$3.89M 2.08% 16
2025
Q4 		$12.2M Sell
262,904
-65,780
-20% -$2.93M 2.53% 18
2025
Q3 		$13.7M Buy
328,684
+30,561
+10% +$977K 3.19% 11
2025
Q2 		$8.57M Buy
+298,123
New +$9.21M 2.09% 16

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Prosight Management's CRNX Position: Q2 2026 in Review

Prosight Management increased its Crinetics Pharmaceuticals (CRNX) stake by 7% in Q2 2026, buying an estimated $917K and bringing the position to 374,666 shares worth $14M. The position accounts for 2.42% of the portfolio, ranked #15.

Prosight Management first reported a position in CRNX in Q2 2025 and has held it in 5 quarters since. 266 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Prosight Management held 374,666 shares of Crinetics Pharmaceuticals worth $14M as of Q2 2026.
  • Prosight Management bought 24,666 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $917K.
  • Crinetics Pharmaceuticals made up 2.42% of Prosight Management's portfolio in Q2 2026, its #15 holding.
  • Prosight Management first reported a position in Crinetics Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 266 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.